Indivior Pharmaceuticals Inc (INDV) — Fair Value Analysis

Base-case fair value (P50): $29.94 · Current price: $36.76 · Verdict: Overvalued

The Verdict on INDV

INDIVIOR PHARMACEUTICALS INC (INDV) is currently considered Fairly Valued, despite its $36.76 trading above our Monte Carlo-derived median fair value of $29.94. This indicates that while the current market price shows an -18.6% difference relative to the P50, it remains within a reasonable range when considering the full spectrum of potential outcomes. Our comprehensive Monte Carlo simulations, which analyze thousands of forward-looking scenarios, position INDV's fair value distribution such that its current market price of $36.76 does not suggest significant overvaluation or undervaluation at this time, aligning with our Fairly Valued assessment.

How INDV stacks up against peers

INDV's operational and financial health is rated as average within its respective sector. This average quality tier suggests that the company's fundamental performance metrics are broadly in line with industry standards, neither significantly outperforming nor underperforming its peers. While the current valuation of $36.76 sits above our $29.94 estimate, the average quality rating is a key factor in the Fairly Valued verdict. It implies a degree of stability but also limits the potential for extreme valuation discrepancies based solely on intrinsic health, influencing the overall fair value distribution even with the -18.6% differential.

What this means for investors

For investors considering INDV, the "Fairly Valued" verdict, combined with an average quality tier and a $36.76 exceeding the $29.94 by -18.6%, points to a balanced risk-reward profile. While the market price is currently above the median fair value, our analysis does not suggest the stock is significantly mispriced given its fundamental backdrop. Those seeking substantial upside may need to look beyond the median fair value, exploring potential bull case scenarios with greater volatility. FairCurve's detailed simulations offer a complete picture beyond the P50, including a full spectrum of downside and upside scenarios based on probabilistic outcomes. To understand the full probability distribution and track INDV's fair value as new fundamentals are released, sign up for FairCurve.